Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03251326 · ClinicalTrials.gov registry record · Phase 1
Nabilone in Cannabis Users With PTSD
A Phase 1 study, sponsored by New York State Psychiatric Institute.
- Terminated
- Registry status
- Phase 1
- Development phase
- 4
- Enrollment target
NCT03251326 is a Phase 1 study that was terminated before completion, run by New York State Psychiatric Institute. The registered enrollment target is 4 participants.
The verdict
NCT03251326, a Phase 1 study, was terminated before completion, sponsored by New York State Psychiatric Institute.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 4 participants
- Enrollment target
Study Summary
Despite the prevalence of cannabis use among the PTSD population and self-reports that it is used to help cope with PTSD symptoms, the direct effects of cannabis on PTSD symptomology are unknown. The purpose of this placebo-controlled, within-subject study is to assess the effects of smoked cannabis and orally administered nabilone, a synthetic analog of THC, the primary psychoactive component of cannabis on multiple dimensions of PTSD symptomatology in cannabis smokers with PTSD.
Interventions
- DRUG Placebo
- DRUG Propranolol
- DRUG Cannabis
- DRUG Nabilone
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 4 participants |
| Start Date | 2015-10 |
| Est. Completion | 2019-06 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03251326
The ClinicalTrials.gov registry entry for NCT03251326 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 4 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is New York State Psychiatric Institute, which has 364 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Placebo is the first listed.
NCT03251326 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03251326 about?
NCT03251326 is a clinical study titled "Nabilone in Cannabis Users With PTSD". Despite the prevalence of cannabis use among the PTSD population and self-reports that it is used to help cope with PTSD symptoms, the direct effects of cannabis on PTSD symptomology are unknown. The purpose of this placebo-controlled, within-subject study is to assess the effects of smoked cannabis...
What is the current status of trial NCT03251326?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 4 participants. The study started on 2015-10. Estimated completion is 2019-06.
What interventions are being tested in trial NCT03251326?
The interventions under investigation include: Placebo (DRUG), Propranolol (DRUG), Cannabis (DRUG), Nabilone (DRUG).
Who is sponsoring clinical trial NCT03251326?
This trial is sponsored by New York State Psychiatric Institute, which has 364 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.